• The company plans to launch 14 products in Brazil, targeting a potential market of USD 2 billion, expanding access to high-complexity treatments in key therapeutic areas, expecting to generate over USD 130 million in sales within the next 4 years.
• Through strategic partnerships with global pharmaceutical leaders, SteinCares will expand access to critical treatments to Brazilian patients with unmet healthcare needs, including those with Bile Acid Synthesis Disorders (BASD), Non-Small Cell Lung Cancer (NSCLC), and R/R Extranodal NK/T-Cell Lymphoma.

San Jose, Costa Rica, February 2024 – SteinCares, a leading specialty healthcare company in Latin America with a solid footprint in more than 30 countries across the region, announces its official expansion into the Brazilian market, marking a key milestone in its regional growth strategy.

Under the leadership of Julio Avella, General Manager for Brazil and LATAM Head of Rare Diseases, the company is set to create access to high-quality treatments from global pharmaceutical partners, making a meaningful impact on patients’ lives.

SteinCares enters Brazil with a clear vision: to shape the future of specialty care through an expanding and diverse portfolio. With 14 licensing agreements already in place —covering key therapeutic areas such as oncology, immunology, and rare diseases, the company is committed to bringing innovative, cost-effective, and high-quality healthcare treatments to patients with unmet medical needs.

Leveraging its regional expertise and strong partnerships with world leading companies, SteinCares is addressing critical healthcare needs, including BASD, NSCLC, and R/R Extranodal NK/T-Cell Lymphoma.

“Expanding into Brazil, a market which accounts for nearly half of the Latin American specialty care sector, is a key step in our strategic growth plan,” says Mitchell Wasserstein, CEO of SteinCares. “This strategic entry triples our addressable market, establishing a strong foundation for growth. With an experienced team led by Julio Avella, and a robust product portfolio, we’re confident in our ability to drive meaningful impact in the country and across the region.”

“We are excited about SteinCares’ potential in Brazil”, adds Julio Avella. “Our high-complexity portfolio, backed by stringent regulatory approvals, ensures high quality and safety for Brazilian patients. This is particularly critical around rare diseases, where patients often face significant challenges accessing effective treatments. We will collaborate closely with the medical community and health authorities to make these vital treatments accessible to all who need them in Brazil”.

With decades of experience, long-standing relationships, and a unique approach to the Latin American healthcare market, SteinCares effectively connects global pharmaceutical companies with regional healthcare providers.

About SteinCares

SteinCares is a leader in commercializing and distributing specialty healthcare products in Latin America, including innovative pharmaceuticals, biosimilars, plasma-derived therapies and complex generics. With more than 40 years of progressive healthcare experience and operations in over 30 countries in Latin America and the Caribbean, SteinCares serves as a bridge between global pharmaceutical companies and the region’s healthcare providers. The company is deeply committed to creating healthcare opportunities that positively impact the lives of patients and their families in Latin America, with a vision of increasing access to innovative and cost-effective healthcare for patients in the region.

For more information, visit http://www.steincares.com/ or follow the company on LinkedIn